This site is intended for healthcare professionals
Oral Anti Coagulation Reversal
Oral Anticoagulation Reversal Learning Zone


Read time: 355 mins
Last updated:1st Dec 2020
Published:29th Jan 2020
Welcome to the Oral Anticoagulation Reversal Learning Zone. This educational resource is designed to help healthcare professionals diagnose, manage and treat bleeding in patients taking anticoagulants.

Recently added: Latest insights in oral anticoagulation and its reversal in our new Key Learnings section with COVID-19 details, and the latest publication digest: Managing bleeds related to oral factor Xa inhibitors with andexanet alfa or replacement agents
Symposia highlights from the 39th International Symposium on Intensive Care And Emergency Medicine 2019.

The aim of this Learning Zone is to give an overview of blood coagulation, anticoagulation, bleeding risk and the various methods for the management and treatment of bleeding in patients taking anticoagulants. Details of blood coagulation factors II, VII, IX and more; the coagulation cascade; haemorrhagic risk assessment, using the international normalised ratio; the factor Xa inhibitors rivaroxaban, edoxaban or apixaban; the factor IIa (thrombin) inhibitor dabigatran; the risks of warfarin treatment; current national and international guidelines; the use of fresh frozen plasma to reverse vitamin K antagonist (VKA) anticoagulation; plasma and rVIIA; and details of the anticoagulation reversal agents idarucizumab, andexanet alpha and ciraparantag are all included in this section.

The Oral Anticoagulants section goes on to provide information on the options available for oral anticoagulation, such as factor Xa and IIa inhibitors. Details of the effects that VKAs can have on patients with atrial fibrillation, heart failure, valvular heart disease, venous thromboembolism and transient ischaemic attacks; the use of paracetamol and an adjuvant therapy; how the CYP2C9 and VKORC1 genes affect blood coagulation; and details of non-vitamin K oral anticoagulants, such as factor Xa inhibitors, rivaroxaban, apixaban, edoxaban, and the factor IIa inhibitor dabigatran are all included in this section.